Apontis Pharma AG
Develops and markets fixed-dose combination drugs (Single Pills) for chronic diseases.
APPH | F
Overview
Corporate Details
- ISIN(s):
- DE000A3CMGM5 (+1 more)
- LEI:
- 894500ETO1J6MR8PDF91
- Country:
- Germany
- Address:
- Alfred-Nobel-Straße 10, 40789 Monheim am Rhein
- Website:
- https://apontis-pharma.de/en/
- Sector:
- Manufacturing
Description
Apontis Pharma AG is a pharmaceutical company that specializes in the development, marketing, and distribution of 'Single Pills'. These are fixed-dose combination drugs that unite two or three active pharmaceutical ingredients into a single tablet. The company's portfolio primarily focuses on treating cardiovascular diseases and other chronic conditions. By simplifying treatment regimens, the Single Pill approach aims to improve patient adherence and therapy outcomes, offering medical and economic benefits to the healthcare system. Apontis Pharma also engages in co-marketing activities for established pharmaceutical products.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-12-16 07:30 |
APONTIS PHARMA strengthens management for future growth: Thomas Zimmermann appo…
|
English | 8.2 KB | ||
| 2021-12-14 07:30 |
APONTIS PHARMA and Midas Pharma announce development partnership to launch Sing…
|
English | 11.3 KB | ||
| 2021-11-18 07:30 |
APONTIS PHARMA grows significantly faster than the overall market in the nine-m…
|
English | 29.6 KB | ||
| 2021-11-18 00:00 |
9M Präsentation (EN)
|
German | 4.0 MB | ||
| 2021-11-18 00:00 |
9M Results Presentation
|
English | 4.0 MB | ||
| 2021-10-26 07:30 |
APONTIS PHARMA announces market launch of new Single Pill
|
English | 9.5 KB | ||
| 2021-09-14 07:30 |
APONTIS PHARMA announces launch of new Single Pill for more efficient treatment…
|
English | 8.9 KB | ||
| 2021-08-11 07:30 |
APONTIS PHARMA builds on strong position and profitability in first half of 202…
|
English | 13.0 KB | ||
| 2021-08-11 00:00 |
H1 Präsentation (EN)
|
German | 3.6 MB | ||
| 2021-08-11 00:00 |
H1 Results Presentation
|
English | 3.6 MB | ||
| 2021-08-11 00:00 |
Half-yearly financial statements 2021
|
German | 355.0 KB | ||
| 2021-07-28 07:30 |
APONTIS PHARMA reports accelerated growth in first half of 2021 - Single Pill r…
|
English | 12.8 KB | ||
| 2021-07-12 07:30 |
APONTIS PHARMA marks further success in the roll-out of Single Pill therapy
|
English | 9.3 KB | ||
| 2021-06-28 00:00 |
Annual financial statements 2020
|
German | 1.3 MB | ||
| 2021-06-18 07:30 |
APONTIS PHARMA AG: Initial studies confirm that the share has a price potential…
|
English | 9.3 KB |
Automate Your Workflow. Get a real-time feed of all Apontis Pharma AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Apontis Pharma AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Apontis Pharma AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-14 | Milz, Thomas | Board | Buy | None | 8,960.00 EUR |
| 2024-05-14 | be executive GmbH | Close relation | Buy | None | 8,880.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 10,128.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 3,396.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 1,692.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 1,688.00 EUR |
| 2023-05-05 | Reineke, Silke | Close relation | Buy | None | 36,625.00 EUR |
| 2023-05-05 | Milz, Thomas | Board | Buy | None | 14,360.00 EUR |
Peer Companies
